Boston Scientific is buying Penumbra for $14.5 billion, gaining entry to ‘fast-growing’ vascular segments




Penumbra’s stock was up about 14% after the deal was announced Thursday morning.


Leave a Reply

Your email address will not be published. Required fields are marked *